
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SEROQUEL | CHEPLAPHARM Arzneimittel | N-020639 RX | 1997-09-26 | 6 products, RLD |
| SEROQUEL XR | CHEPLAPHARM Arzneimittel | N-022047 RX | 2007-05-17 | 5 products, RLD |
Brand Name | Status | Last Update |
|---|---|---|
| quetiapine | ANDA | 2025-09-25 |
| quetiapine fumarate | ANDA | 2025-09-22 |
| quetiapine fumarate er | ANDA | 2025-09-26 |
| seroquel | New Drug Application | 2025-06-13 |
| seroquel xr | 2008-01-17 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 12 | 14 | 47 | 54 | 54 | 178 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 3 | 7 | 39 | 35 | 35 | 117 |
| Psychotic disorders | D011618 | — | F20.81 | 3 | 2 | 17 | 26 | 16 | 63 |
| Depression | D003863 | — | F33.9 | 7 | 9 | 22 | 13 | 10 | 60 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 5 | 5 | 16 | 10 | 13 | 49 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 6 | 3 | 13 | 5 | 14 | 41 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | 10 | 10 | 5 | 26 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | 1 | 7 | 5 | 5 | 18 |
| Mania | D000087122 | — | F30 | — | 2 | 4 | 6 | 4 | 16 |
| Delirium | D003693 | — | R41.0 | 2 | 3 | 6 | 2 | 4 | 15 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 2 | 1 | — | — | 4 |
| Borderline personality disorder | D001883 | — | F60.3 | — | 1 | 2 | — | — | 3 |
| Disease progression | D018450 | — | — | 1 | — | 1 | — | — | 2 |
| Personality disorders | D010554 | — | F60.6 | — | — | 2 | — | — | 2 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Psychotic affective disorders | D000341 | — | F39 | — | — | 1 | — | — | 1 |
| Sleep | D012890 | GO_0030431 | — | — | — | 1 | — | — | 1 |
| Mental health | D008603 | EFO_0003935 | — | — | — | 1 | — | — | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | 2 | 1 | — | — | 1 | 4 |
| Accelerated idioventricular rhythm | D016170 | — | — | — | 2 | — | — | — | 2 |
| Smoking | D012907 | EFO_0004318 | — | — | 1 | — | — | 1 | 2 |
| Disease | D004194 | EFO_0000408 | R69 | — | 1 | — | — | 1 | 2 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | 1 | — | — | 1 | 2 |
| Anhedonia | D059445 | — | R45.84 | — | 1 | — | — | — | 1 |
| Tobacco use disorder | D014029 | — | F17 | — | 1 | — | — | — | 1 |
| Marijuana smoking | D008385 | — | — | — | 1 | — | — | — | 1 |
| Marijuana use | D000074609 | — | — | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Body weight | D001835 | EFO_0004338 | — | 1 | — | — | — | — | 1 |
| Respiratory insufficiency | D012131 | — | J96.9 | 1 | — | — | — | — | 1 |
| Hypercapnia | D006935 | — | — | 1 | — | — | — | — | 1 |
| Movement disorders | D009069 | EFO_0004280 | G25 | 1 | — | — | — | — | 1 |
| Dyskinesias | D020820 | — | G24 | 1 | — | — | — | — | 1 |
| Drug-induced dyskinesia | D004409 | EFO_1000904 | — | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Lecithin cholesterol acyltransferase deficiency | D007863 | — | E78.6 | 1 | — | — | — | — | 1 |
| Fasting | D005215 | EFO_0002756 | — | 1 | — | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 2 | 2 |
| Hyperprolactinemia | D006966 | — | E22.1 | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Sleep deprivation | D012892 | — | F51.12 | — | — | — | — | 1 | 1 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 1 | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
| Hyperglycemia | D006943 | — | R73.9 | — | — | — | — | 1 | 1 |
| Micrognathism | D008844 | — | M26.04 | — | — | — | — | 1 | 1 |
| Drug common name | Quetiapine |
| INN | quetiapine |
| Description | Quetiapine is a dibenzothiazepine, a N-alkylpiperazine and a N-arylpiperazine. It has a role as a serotonergic antagonist, a dopaminergic antagonist, a histamine antagonist, an adrenergic antagonist and a second generation antipsychotic. |
| Classification | Small molecule |
| Drug class | tricyclic compounds; antipsychotics (dibenzothiazepine derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1 |
| PDB | — |
| CAS-ID | 111974-69-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL716 |
| ChEBI ID | 8707 |
| PubChem CID | 5002 |
| DrugBank | DB01224 |
| UNII ID | BGL0JSY5SI (ChemIDplus, GSRS) |








